NCT07252232 (RASolute 304) is a Phase 3 clinical trial of daraxonrasib in Pancreatic Cancer, sponsored by Revolution Medicines, Inc..

Who is sponsoring NCT07252232?

NCT07252232 is sponsored by Revolution Medicines, Inc..

What drugs are being tested in NCT07252232?

Interventions in NCT07252232: daraxonrasib.

What condition does NCT07252232 study?

NCT07252232 studies Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma.

Is NCT07252232 still recruiting?

NCT07252232 is currently recruiting now. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT07252232: RASolute 304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting now Phase 3 Last updated 6 April 2026

What this trial tests

Phase 3 trial testing daraxonrasib in Pancreatic Cancer in 500 participants. Currently enrolling.

Timeline

15 December 2025

Primary endpoint
10 May 2029

10 July 2030

Quick facts

Lead sponsor	Revolution Medicines, Inc.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	15 December 2025
Primary completion	10 May 2029
Estimated completion	10 July 2030
Sites	15 locations across United Kingdom, Puerto Rico, United States

Drugs / interventions tested

daraxonrasib — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
PDAC — all drugs for PDAC →
PDAC - Pancreatic Ductal Adenocarcinoma — all drugs for PDAC - Pancreatic Ductal Adenocarcinoma →
Resectable Pancreatic Ductal Adenocarcinoma (PDAC) — all drugs for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) →

Sponsor

Revolution Medicines, Inc. — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer or PDAC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review.
Muddasani A, Abdelnoor A, Manne A. · · 2026 · PMID 42193022 · DOI 10.3390/cancers18101664

Verify or expand the search:

Other trials of daraxonrasib

Trials testing the same drug.

NCT06881784 — Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) · Phase 3 · recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Revolution Medicines, Inc. trials

Trials by the same sponsor.

NCT06881784 — Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) · Phase 3 · recruiting
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06040541 — Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors · Phase 1 · recruiting
NCT05462717 — Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors · Phase 1 · active not recruiting
NCT05379985 — Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07252232 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Revolution Medicines, Inc.
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07252232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing